Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic

Bone Marrow Transplantation volume 58, pages 1394–1396 (2023)Cite this article

Subjects

Access through your institution
Buy or subscribe

Between 2020 and 2022, the SARS-CoV-2 pandemic had a substantial impact on the global healthcare asset [1].

Since 2019, the standard management of several relapsed/refractory hematological malignancies was revolutionized by anti-CD19 chimeric antigen receptor T-cells (CAR-T). Results have been impressive, with around 40% achieving durable complete remission. Delivery of CAR-T involves numerous logistic steps, including patients referral apheresis scheduling, administration of bridge therapy, hospitalization for lymphodepletion and CAR-T reinfusion, management of early and late toxicities.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Heatmap of the prophylactic status of CAR-T patients according to the three enrollment ERAs.

Data availability

For data availability, please contact the corresponding author.

References

  1. Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, et al. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open. 2022;7:100403. https://doi.org/10.1016/J.ESMOOP.2022.100403

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Pagano L, Salmanton-García J, Marchesi F, Blennow O, Gomes da Silva M, Glenthøj A, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey. Blood. 2022;140:2773–87. https://doi.org/10.1182/blood.2022017257

    Article  CAS  PubMed  Google Scholar 

  3. Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021;35:3585–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lemoine J, Bachy E, Cartron G, Beauvais D, Gastinne T, Rubio MT, et al. Causes and risk factors of early and late non-relapse mortality after CD19 CAR T-cell therapy for diffuse large B-cell lymphoma (DLBCL): a Lysa Study from the Descar-T Registry. Blood. 2022;140:1859–61.

    Article  Google Scholar 

  5. Agenzia Italiana del Farmaco Determina 15 febbraio 2022 Definizione delle modalita’ e delle condizioni di impiego dell’associazione di anticorpi monoclonali Evusheld (AZD7442; tixagevimab-cilgavimab) ai sensi del decreto 20 gennaio 2022. (Determina n. DG/87/2022) (22A01225). https://www.aifa.gov.it/registri-e-piani-terapeutici1. Accessed 25 Jan 2023.

  6. Infante MS, DeWolf S, Tamari R, Dahi PB, Lee YJ, Politikos I, et al. Outcomes and management of Sars-CoV2 Omicron variant in recipients of hematopoietic cell transplantation (HCT) and CAR-T therapy. Blood. 2022;140:4792–4.

    Article  Google Scholar 

  7. SARS-CoV-2 variants of concern as of 17 May 2023. https://www.ecdc.europa.eu/en/covid-19/variants-concern. Accessed 23 May 2023.

  8. Lin L, Liu Y, Tang X, He D. The disease severity and clinical outcomes of the SARS-CoV-2 variants of concern. Front Public Health. 2021;9:775224. https://doi.org/10.3389/FPUBH.2021.775224

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the support of “Centro di Ricerca sulle cellule staminali emopoietiche e le terapie cellulari “Università Cattolica del Sacro Cuore, Roma” research funding. The authors thank also John D. Marra, MD, for support in medical English.

Author information

Author notes

  1. These authors contributed equally: Eugenio Galli, Alice Di Rocco.

Authors and Affiliations

  1. Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

    Eugenio Galli, Elisabetta Metafuni, Nicola Piccirillo, Maria Bianchi, Stefan Hohaus, Patrizia Chiusolo, Simona Sica & Federica Sorà

  2. Dipartimento di Medicina Traslazionale e di Precisione, Università di Roma Sapienza, Rome, Italy

    Alice Di Rocco, Martina Di Palma, Giovanni Fernando Torelli, Anna Paola Iori & Maurizio Martelli

  3. Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy

    Ilaria Pansini, Nicola Piccirillo, Stefan Hohaus, Patrizia Chiusolo, Simona Sica & Federica Sorà

  4. Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, Italy

    Federico Frondizi & Antonella Cingolani

  5. Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

    Antonella Cingolani

Authors
  1. Eugenio Galli
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Alice Di Rocco
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Ilaria Pansini
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Federico Frondizi
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Martina Di Palma
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Elisabetta Metafuni
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Nicola Piccirillo
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Maria Bianchi
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Antonella Cingolani
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Giovanni Fernando Torelli
    View author publications

    You can also search for this author inPubMed Google Scholar

  11. Stefan Hohaus
    View author publications

    You can also search for this author inPubMed Google Scholar

  12. Patrizia Chiusolo
    View author publications

    You can also search for this author inPubMed Google Scholar

  13. Anna Paola Iori
    View author publications

    You can also search for this author inPubMed Google Scholar

  14. Simona Sica
    View author publications

    You can also search for this author inPubMed Google Scholar

  15. Maurizio Martelli
    View author publications

    You can also search for this author inPubMed Google Scholar

  16. Federica Sorà
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

EG, ADR, and FS designed the study and drafted the paper. SH, PC, SS, AC, API and MM supervised the study and critically revised the paper. NP and MB supervised the fluency of collection and management of cellular products. EG, ADR, MDP, IP, and FF collected data. EG performed statistical analysis. FF, EM and AC managed the infectious complications of patients. All authors have critically reviewed and approved the paper.

Corresponding author

Correspondence to Simona Sica.

Ethics declarations

Competing interests

EG received travel grants from Kite Gilead and honoraria for speakers bureau from Novartis and advisory board from Bristol Myers Squibb. SH received honoraria for participating to advisory boards from Novartis. PC received honoraria for participating to advisory boards from Bristol Myers Squibb and Novartis. All other authors declare no competing conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galli, E., Di Rocco, A., Pansini, I. et al. Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic. Bone Marrow Transplant 58, 1394–1396 (2023). https://doi.org/10.1038/s41409-023-02093-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-023-02093-2

Search

Advanced search

Quick links